ReviewHaematologica2018
Review in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- ZNF292 mutations impair RNA and protein biosynthesis defining an adverse prognostic subset in early-stage chronic lymphocytic leukemia.Biomarker research · 2026Article
- ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia.Blood advances · 2026Article
- Unexpected Durable Treatment-Free Disease Control After Acalabrutinib Cessation: A Case Report.Cureus · 2026Article
- A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept Study.Journal of clinical medicine · 2026Article
- Application of Fluorescence in situ Hybridization in Malignant Hemopathies: First Experience from Albania.Balkan journal of medical genetics : BJMG · 2026Article
- ComplexInternational journal of molecular sciences · 2026Review
- Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Article
- Article
- Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa.Applied health economics and health policy · 2026Article
- Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy.Leukemia research reports · 2026Article
- Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice.Frontiers in oncology · 2026Review
- Article
- Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL.Blood advances · 2025Article
- Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States.Cancers · 2025Article
- The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs.Biomolecules · 2025Review
- Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives.Hematology reports · 2025Review
- Article
- Targeting Tumor Microenvironment Interactions in Chronic Lymphocytic Leukemia Using Leukotriene Inhibitors.International journal of molecular sciences · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.